July 7, 2022
SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR ENALAPRIL MALEATE TABLETS
SOMERSET, NJ — Solco Healthcare announces its FDA approval for Enalapril Maleate tablets, 2.5mg, 5mg, 10mg and 20mg which are AB-rated equivalent to Vasotec® by Bausch Health.
“This product was developed by our subsidiary – Prinbury Biopharm for Solco. This approval represents Solco’s continue commitment to developing and marketing high quality and cost-effective ACE inhibitors and being a leader in that space”, said Hai Wang, President of Solco Healthcare. Enalapril Maleate tablets are indicated for the control of hypertension. According to IQVIA, total market sales for Enalapril Maleate tablets for the last twelve months ending August 2022 were $37.08 million.
Solco Healthcare will market Enalapril Maleate tablets in 100 and 1000 count bottles. The product is now available. Please contact your Solco Healthcare National Accounts Director or customer service at (855) 581-9688 for more information.